Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma358
Reply to correspondence on “Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis”294
Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications216
Correspondence to editorial on “Integrated Molecular Characterization of Sarcomatoid Hepatocellular Carcinoma”195
Reply to correspondence on “The Burden of Steatotic Liver Disease before and during the COVID Pandemic”186
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity154
Reply to correspondence to editorial on “Bariatric Surgery Reduces Long-Term Mortality in Patients with MASLD and Cirrhosis”102
Deciphering adenosine signaling in hepatocellular carcinoma: pathways, prognostic models, and therapeutic implications94
TM4SF1 - A new immune target for treatment of hepatocellular carcinoma74
Baveno VI-SSM was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis74
Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”72
TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure?70
KASL clinical practice guidelines for management of autoimmune hepatitis 202267
Another oral antiviral treatment, but still far away from hepatitis B virus cure65
Microbiome and metabolomics in alcoholic liver disease65
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B64
Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: a nonnegligible risk to liver-related health61
Correspondence to “Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer”59
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”57
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy51
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues50
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”49
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”48
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China48
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”45
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”45
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus45
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”43
Correspondence to editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”41
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments41
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial39
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis39
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”39
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”39
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”38
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)37
0.089834928512573